Hangzhou Yi Wen Race Biotechnology

Evenrace Biotechnology is a Chinese biopharmaceutical company specializing in the development of next-generation, off-the-shelf cell therapies using induced pluripotent stem cell (iPSC) technology. Based in Hangzhou, the company focuses on creating universal cell products, particularly iPSC-derived natural killer (NK) cells and T cells, to treat various cancers. By leveraging its proprietary iPSC platform, Evenrace aims to overcome the limitations of traditional autologous cell therapies, such as high manufacturing costs and limited scalability. The company's leadership includes veterans from global biopharma firms like Kite Pharma and Amgen, and it has received significant backing from prominent investors to advance its pipeline toward clinical trials.